Ken Griffin
CHRS icon

Ken Griffin’s Coherus Oncology CHRS Stock Holding History

Ken Griffin’s Portfolio CHRS Stock Details CHRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$204K Buy
121,000
+100,000
+476% +$178K ﹤0.01% 11371
2025
Q4 		$29.8K Sell
21,000
-98,700
-82% -$144K ﹤0.01% 12226
2025
Q3 		$196K Buy
119,700
+88,700
+286% +$98.7K ﹤0.01% 11285
2025
Q2 		$22.7K Sell
31,000
-34,300
-53% -$29.6K ﹤0.01% 12077
2025
Q1 		$52.7K Sell
65,300
-26,500
-29% -$30.5K ﹤0.01% 12262
2024
Q4 		$127K Buy
91,800
+52,300
+132% +$58.7K ﹤0.01% 11111
2024
Q3 		$41.1K Sell
39,500
-11,400
-22% -$15.6K ﹤0.01% 12122
2024
Q2 		$88.1K Sell
50,900
-34,700
-41% -$69.8K ﹤0.01% 11095
2024
Q1 		$205K Sell
85,600
-38,384
-31% -$94.5K ﹤0.01% 10279
2023
Q4 		$413K Buy
123,984
+69,684
+128% +$187K ﹤0.01% 8502
2023
Q3 		$203K Buy
54,300
+14,100
+35% +$65.1K ﹤0.01% 9883
2023
Q2 		$172K Buy
40,200
+32,600
+429% +$192K ﹤0.01% 10119
2023
Q1 		$52K Sell
7,600
-31,400
-81% -$244K ﹤0.01% 12097
2022
Q4 		$309K Buy
+39,000
New +$300K ﹤0.01% 9254
2021
Q4 		– Sell
-14,100
Closed -$227K – 13860
2021
Q3 		$227K Sell
14,100
-11,200
-44% -$164K ﹤0.01% 11700
2021
Q2 		$350K Buy
25,300
+400
+2% +$5.67K ﹤0.01% 10890
2021
Q1 		$364K Buy
24,900
+9,800
+65% +$166K ﹤0.01% 10394
2020
Q4 		$262K Buy
+15,100
New +$269K ﹤0.01% 9298
2020
Q2 		– Sell
-10,300
Closed -$167K – 9834
2020
Q1 		$167K Sell
10,300
-5,300
-34% -$97.9K ﹤0.01% 8185
2019
Q4 		$281K Buy
15,600
+5,600
+56% +$103K ﹤0.01% 7680
2019
Q3 		$203K Sell
10,000
-1,900
-16% -$38K ﹤0.01% 8134
2019
Q2 		$263K Buy
+11,900
New +$207K ﹤0.01% 7783
2019
Q1 		– Sell
-17,100
Closed -$155K – 9300
2018
Q4 		$155K Sell
17,100
-2,700
-14% -$31.2K ﹤0.01% 8035
2018
Q3 		$327K Buy
+19,800
New +$351K ﹤0.01% 7428
2017
Q3 		– Sell
-11,500
Closed -$165K – 7568
2017
Q2 		$165K Buy
+11,500
New +$221K ﹤0.01% 6674

Other funds holding CHRS

TGY2IT
Timothy G. Youngquist 2020 Irrevocable Trust Fort Myers, Florida $510M AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
CM
CM Management Gulf Breeze, Florida $157M AUM 60.08% 1-Year Est. Return

Ken Griffin's CHRS Position: Q1 2026 in Review

Ken Griffin opened a new position in Coherus Oncology (CHRS) in Q1 2026: 233,946 shares worth $395K. The stake represents ﹤0.01% of the portfolio and ranks #9843 among its holdings. This is a return to the name: Ken Griffin previously reported a position in CHRS as recently as Q3 2025.

Ken Griffin first reported a position in CHRS in Q1 2015 and has held it in 38 quarters since. The position peaked at $34.3M in Q1 2019. 158 funds tracked by Wall St. Rank hold CHRS as of Q1 2026.

  • Ken Griffin held 233,946 shares of Coherus Oncology worth $395K as of Q1 2026.
  • Coherus Oncology was a new Ken Griffin position in Q1 2026.
  • Coherus Oncology made up ﹤0.01% of Ken Griffin's portfolio in Q1 2026, its #9843 holding.
  • Ken Griffin first reported a position in Coherus Oncology in Q1 2015 and has held it in 38 quarters since.
  • Ken Griffin's Coherus Oncology position peaked at $34.3M in Q1 2019.
  • 158 funds tracked by Wall St. Rank held Coherus Oncology as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.